Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	7.25	12.09	-92.93	2.3
Depreciation & Amortization	1.71	1.59	1.11	1.13
Loss (Gain) From Sale of Assets	0.06	0.07	3.34	0
Asset Writedown & Restructuring Costs	-	-	83.1	-
Loss (Gain) on Equity Investments	0.06	0.04	1.31	0.25
Stock-Based Compensation	1.33	0.83	7.28	13.37
Provision & Write-off of Bad Debts	0.37	0.17	-0.06	0.02
Other Operating Activities	4.01	4.44	6.02	1.4
Change in Accounts Receivable	-3.74	-5.26	0.29	-7.92
Change in Inventory	-3.01	-2.14	1.75	-0.88
Change in Accounts Payable	-0.21	-0.25	0.19	-0.11
Change in Income Taxes	-5.86	-2.17	3	-1.34
Change in Other Net Operating Assets	-8.62	-13.05	11.49	2.46
Operating Cash Flow	-6.65	-3.64	25.89	10.68
Operating Cash Flow Growth	-	-	142.50%	-
Capital Expenditures	-2.21	-2.32	-8.52	-4.99
Sale of Property, Plant & Equipment	0.35	0.4	0.66	-
Cash Acquisitions	-	-	5.46	-
Divestitures	-	-	-0.57	-
Sale (Purchase) of Intangibles	-1.51	-0.81	-0.07	-0.01
Investment in Securities	-7.33	-17.16	-16.74	-8.82
Investing Cash Flow	-10.7	-19.88	-19.76	-13.81
Issuance of Common Stock	3.45	2.64	-	-
Other Financing Activities	-0.66	-0.54	-	-
Financing Cash Flow	2.79	2.1	2.5	-
Foreign Exchange Rate Adjustments	-0.18	-0.27	-0.3	-1.89
Net Cash Flow	-14.74	-21.7	8.33	-5.03
Free Cash Flow	-8.86	-5.96	17.38	5.69
Free Cash Flow Growth	-	-	205.25%	-
Free Cash Flow Margin	-8.80%	-5.63%	15.32%	5.56%
Free Cash Flow Per Share	-0.09	-0.06	0.26	0.07
Cash Income Tax Paid	10.44	8.52	6.35	6.31
Levered Free Cash Flow	-8.55	-6	20.67	-
Unlevered Free Cash Flow	-8.55	-6	20.67	-
Change in Net Working Capital	14.39	15.44	-8.85	-

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q